Article info

Download PDFPDF
Systematic review
Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone)
  1. Correspondence to Victor G Vogel
    American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA; victor.vogel{at}cancer.org
View Full Text

Citation

Vogel VG
Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone)

Publication history

  • First published August 3, 2010.
Online issue publication 
August 03, 2010

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.